Advertisement

Advertisement

Hematology Expert Review

Leukemia

B-Cell Acute Lymphoblastic Leukemia: Update on Clinical Trials

Syed Ali Abutalib, MD, and Jacob M. Rowe, MD  /  July 25, 2021

“Learning never exhausts the mind.” —Leonardo da Vinci To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on treatments under stud...

Hematologic Malignancies

Novel Targeted Agents for the Treatment of Myelofibrosis

Syed Ali Abutalib, MD, and Ruben A. Mesa, MD, FACP  /  July 10, 2021

“Progress lies not in enhancing what is, but in advancing toward what will be.”                                                              –Kahlil Gibran To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition...

Multiple Myeloma

Newly Diagnosed Multiple Myeloma

Syed Ali Abutalib, MD, and Kenneth C. Anderson, MD  /  June 25, 2021

“Continuous improvement is better than delayed perfection.” —Mark Twain To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on ...

Hematologic Malignancies

Selected ASH Abstracts on Novel Treatments of Polycythemia Vera

Syed Ali Abutalib, MD, and Ruben A. Mesa, MD, FACP  /  December 25, 2020

To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are three abstracts selected from the meeting proceedings focusing on novel therapies for polycythemia vera. For full details of these study abstr...

Leukemia

Update on Clinical Trials in Acute Myeloid Leukemia

Syed Ali Abutalib, MD, and Farhad Ravandi, MD  /  June 10, 2021

To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on acute myeloid leukemia (AML), such as the use of venetoclax added to cladr...

COVID-19

Coagulopathy and COVID-19 Infection

Syed Ali Abutalib, MD, and Jean M. Connors, MD  /  May 25, 2021

“Life is short, art long, opportunity fleeting, experience treacherous, judgment difficult.” —Hippocrates To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the me...

Myelodysplastic Syndromes

Novel Insights in Myelodysplastic Syndromes: Highlights From 2020 ASH Meeting

Syed Ali Abutalib, MD, and Peter Greenberg, MD  /  April 10, 2021

To complement The ASCO Post’s comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel clinical trial findings in myelodysplastic syndromes (MDS). For full details of th...

Immunotherapy
Hematologic Malignancies

Bispecific Antibody Platform: Early Data in Relapsed and Refractory Myeloma

Syed Ali Abutalib, MD, and Kenneth C. Anderson, MD  /  May 10, 2021

“There was never a night or a problem that could defeat sunrise or hope.” —Bernard Williams To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceed...

Multiple Myeloma
Immunotherapy

Anti-BCMA–Directed CAR T-Cell Gene Therapy in Relapsed or Refractory Myeloma

Syed Ali Abutalib, MD, and Kenneth C. Anderson, MD  /  April 25, 2021

"The noblest pleasure is the joy of understanding.” —Leonardo da Vinci To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel...

Leukemia

Novel Approaches in Chronic Lymphocytic Leukemia

Syed Ali Abutalib, MD, and Jennifer R. Brown, MD, PhD  /  February 25, 2021

To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapeutic approaches in chronic lymphocytic leukemia (CLL). For full d...

Lymphoma
Immunotherapy

Challenges in Managing Hodgkin Lymphoma: Focus on Use of Brentuximab Vedotin

Syed Ali Abutalib, MD, and Julie M. Vose, MD, MBA, FASCO  /  March 25, 2021

“I was taught that the way of progress was neither swift nor easy.” —Marie Curie To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are two abstracts selected from the meeting proceedings focusing on...

Lymphoma
Immunotherapy

B-Cell and T-Cell Non-Hodgkin Lymphomas

Syed Ali Abutalib, MD, and Julie M. Vose, MD, MBA, FASCO  /  February 25, 2021

To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on the assessment and treatment of patients with B-cell and T-cell non-Hodgkin ly...

Hematologic Malignancies

Novel Therapies Under Study in Chronic Myeloid Leukemia

Syed Ali Abutalib, MD, and Michael J. Mauro, MD  /  March 10, 2021

“There is progress whether ye are going forward or backward! The thing is to move.” —Edgar Cayce To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are a few abstracts selected from the meeting proce...

Multiple Myeloma
Immunotherapy

Novel Insights Into Multiple Myeloma

Syed Ali Abutalib, MD, and Kenneth C. Anderson, MD, FASCO  /  February 10, 2021

“Knowledge has a beginning but no end.” —Geeta Iyengar To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are three abstracts selected from the meeting proceedings focusing on novel therapies for mul...

Hematologic Malignancies

Allogeneic Hematopoietic Cell Transplantation in Acute Leukemias and Myelodysplastic Syndromes

Syed Ali Abutalib, MD, and Elizabeth J. Shpall, MD  /  January 25, 2021

To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on the use of allogeneic hematopoietic cell transplantation (allo-HCT) in the...

Lymphoma

Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Neoplasms

Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD  /  December 10, 2020

The ASCO Post is pleased to present the Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Medeiros explore extranodal marginal zone lymphoma of mucosa-associated lymphoid neoplasms (MALT lymphomas). For each quiz questio...

Lymphoma

The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD  /  October 25, 2020

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Syed Ali Abutalib and L. Jeffrey Medeiros explore the updated World Health Organization (WHO) classification of hematopoietic and lymphoid tissue m...

Multiple Myeloma
Immunotherapy

Updates on BCMA-Directed CAR-Modified T-Cell Gene Therapies

Syed Ali Abutalib, MD, and Shaji K. Kumar, MD  /  September 25, 2020

Outcomes in patients with triple-class–failure relapsed and refractory multiple myeloma who experience disease progression on immunomodulatory agents, proteasome inhibitors, and CD38 antibodies are dismal. Most recently, early results of three anti-B-cell maturation antigen (BCMA) chimeric antigen r...

Multiple Myeloma

Red Flag Presentations of Immunoglobulin Light Chain Amyloidosis in Patients With Multiple Myeloma

Syed Ali Abutalib, MD, Lisa Mendelson, APRN-BC, and Vaishali Sanchorawala, MD  /  October 10, 2020

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that occasionally quizzes readers on issues in hematology. In this installment, the authors highlight the most common type of systemic amyloidosis in the United States: immunoglobulin light chain [or amyloid light chain...

Hematologic Malignancies
Immunotherapy

Update on Novel Immunotherapies for Plasma Cell Disorders

Syed Ali Abutalib, MD, and Luciano J. Costa, MD, PhD  /  September 10, 2020

In this installment of The ASCO Post’s Hematology Expert Review, we take a closer look at the monoclonal antibody targeting CD38, daratumumab, in the treatment of amyloid light chain (AL) amyloidosis and resistant multiple myeloma as well as the antibody-drug conjugate belantamab mafodotin-blmf, w...

Hematologic Malignancies

The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

Syed Ali Abutalib, MD, Naveen Pemmaraju, MD, and L. Jeffrey Medeiros, MD  /  August 25, 2020

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that occasionally quizzes readers on issues in hematology. In this installment, Drs. Abutalib, Pemmaraju, and Medeiros highlight the clinically aggressive blastic plasmacytoid dendritic cell neoplasm. For each quiz ques...

Lymphoma

Selected ASH Abstracts on Novel Treatments for Non-Hodgkin Lymphomas

Syed Ali Abutalib, MD, AND Sonali M. Smith, MD, FASCO  /  April 25, 2020

To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapies for patients with non-Hodgkin lymphomas (NHLs). For full...

Lymphoma
Immunotherapy

Highlights of Research in Lymphomas Presented During the EHA25 Virtual Congress

Syed Ali Abutalib, MD, and Brad Kahl, MD  /  August 10, 2020

To complement The ASCO Post’s continued coverage of the virtual edition of the 25th European Hematology Association Annual Congress (EHA25 Virtual), here are a few abstracts selected from the meeting proceedings focusing on clinical research in Hodgkin and marginal zone lymphomas. Omission of Rad...

Lymphoma

The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD  /  June 25, 2020

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that occasionally quizzes readers on issues in hematology. In this first-part of a two-part installment, Drs. Abutalib and Medeiros highlight the histologically rare lymphocyte-rich type of classic Hodgkin lymphom...

Lymphoma

The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD  /  June 25, 2020

Question 1 Which of the following statements about mixed-cellularity classic Hodgkin lymphoma is correct? A. It has a female predominance. B. This type of classic Hodgkin lymphoma is relatively more common in developing nations and is frequently associated with Epstein-Barr virus (EBV) positivity...

Hematologic Malignancies
COVID-19

Cancer and COVID-19: Considerations About Neutropenia, Anemia, and Thrombocytopenia

Syed Ali Abutalib, MD and Saad Z. Usmani, MD, FACP  /  June 10, 2020

GUEST EDITORS Dr. Abutalib is Associate Director of the Hematology and Cellular Therapy Program and Director of the Clinical Apheresis Program at Cancer Treatment Centers of America, Zion, Illinois; Associate Professor at the Roseland Franklin University of Medicine and Science; and Founder and Co-...

COVID-19

Hypercoagulability in Critically Ill Patients With COVID-19: Where Do We Stand?

Syed Ali Abutalib, MD, and Jean M. Connors, MD  /  May 25, 2020

“Life is short, art long, opportunity fleeting, experience treacherous, judgment difficult.” ―Hippocrates The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that occasionally quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Connors consi...

Hematologic Malignancies
Immunotherapy

Highlights From Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR

Syed Ali Abutalib, MD, and Parameswaran Hari, MD  /  April 10, 2020

The Combined Annual Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) were held in Orlando, Florida, from February 19–23, 2020. The scientific program addressed the most timely issues in ...

Leukemia
Lymphoma

Selected ASH Abstracts on Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Syed Ali Abutalib, MD, and John M. Pagel, MD, PhD  /  March 25, 2020

ABSTRACT 355: MURANO study: Four-year analysis confirms sustained benefit (compared to bendamustine and rituximab; n = 195) of time-limited venetoclax/rituximab (n = 194) in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; ClinicalTrials.gov NCT02005471)1 Met...

Leukemia
Lymphoma

Selected ASH Abstracts on Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Syed Ali Abutalib, MD, and John M. Pagel, MD, PhD  /  March 25, 2020

To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapies for newly diagnosed chronic lymphocytic leukemia (CLL) and sma...

Leukemia
Immunotherapy

Selected ASH Abstracts on Novel Treatments in Acute Lymphoblastic Leukemia

Syed Ali Abutalib, MD, and Daniel J. DeAngelo, MD, PhD  /  March 10, 2020

To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapies for newly diagnosed and relapsed or refractory acute lymphobla...

Hematologic Malignancies

Updates in Hematopoietic Cell Transplantation

Syed Ali Abutalib, MD, and Navneet Majhail, MD, MS  /  February 25, 2020

To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on allogeneic and autologous hematopoietic cell transplantation. For full details...

CAR T-Cell Gene Therapy in Non-Hodgkin Lymphomas: Present and Future

SYED ALI ABUTALIB, MD, AND SATTVA S. NEELAPU, MD  /  February 10, 2020

To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel immunotherapies for patients with different types of non-Hodgkin lymphom...

Selected ASH Abstracts on Myelodysplastic Syndromes

SYED ALI ABUTALIB, MD, and ALAN F. LIST, MD  /  February 10, 2020

To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapies for myelodysplastic syndromes (MDS), including the first...

Lymphoma

The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

Syed A. Abutalib, MD, and L. Jeffrey Medeiros, MD  /  December 25, 2019

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD, explore the updated World Health Organization (WHO) classification of hematopoietic and ly...

Hematologic Malignancies
Immunotherapy

Answers to Hematology Expert Review Questions

Syed Ali Abutalib, MD; Hamza Hashmi, MD; and David L. Porter, MD  /  November 25, 2019

Question 1 Which of the following statements about cytokine-release syndrome and neurotoxicity after tisagenlecleucel infusion is correct? Correct answer: B. The median time to onset of cytokine-release syndrome is 3 days. Expert Perspective Following tisagenlecleucel infusion, cytokine-release ...

Lymphoma

The World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues

Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD  /  November 25, 2019

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Medeiros explore the updated World Health Organization (WHO) classification of nodular lymphocyte-predominant Hodgkin lymphoma. For ea...

Lymphoma

Answers to Hematology Expert Review Questions

Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD  /  November 25, 2019

Question 1 Which of the following statements about nodular lymphocyte-predominant HL is correct? Correct answer: A. Nodular lymphocyte-predominant HL can transform into large B-cell lymphoma. Expert Perspective Nodular lymphocyte-predominant HL is a B-cell neoplasm characterized by a nodular or ...

Hematologic Malignancies
Immunotherapy

CAR T-Cell Gene Therapy: Toxicities and Management Principles

Syed Ali Abutalib, MD; Hamza Hashmi, MD; and David L. Porter, MD  /  November 25, 2019

“Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.”                                                                                                                  —Marie Curie The ASCO Post is pleased to present Hematolog...

Hematologic Malignancies

Gene Therapy: A March Forward!

Syed A. Abutalib, MD, and Uroosa Ibrahim, MD  /  October 10, 2019

GUEST EDITORS Dr. Abutalib is Associate Director, Hematology and Cellular Therapy Program and Director, Clinical Apheresis Program Cancer Treatment at Centers of America, Zion, Illinois; Associate Professor, Rosalind Franklin University of Medicine and Science; and Founder and Co-Editor of Adva...

Leukemia
Immunotherapy

Update on Treatments Under Study for Chronic Lymphocytic Leukemia

Syed Ali Abutalib, MD, and Sonali M. Smith, MD, FASCO  /  September 25, 2019

The ASCO Post has offered comprehensive coverage of the 2019 ASCO Annual Meeting. To complement this news coverage, here are featured clinical trials of several treatments in chronic lymphocytic leukemia (CLL). They focus on the monoclonal antibody obinutuzumab in combination therapy in the CLL14 tr...

Hematologic Malignancies

The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

Syed A. Abutalib, MD, and L. Jeffrey Medeiros, MD  /  May 10, 2019

GUEST EDITORS Dr. Abutalib is Assistant Director, Hematology and Hematopoietic Cell Transplantation Director, Hematopoietic Cell Transplant Apheresis Service, Cancer Treatment Centers of America, Zion, Illinois, Editor-in-Chief, Advances in Cell & Gene Therapy. Dr. Medeiros is Professor and...

Lymphoma

Update on Newer Treatments in Non-Hodgkin Lymphomas

Syed Ali Abutalib, MD, and Matthew Lunning, DO  /  March 10, 2019

AS PART of The ASCO Post’s continued coverage of the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition, here is an update on several different studies on new therapeutics in non-Hodgkin lymphomas (NHLs), including follicular lymphoma, diffuse large B-cell lymphoma (DLBCL)...

Multiple Myeloma

Updated International Myeloma Working Group Criteria: Diagnostic Challenges

Syed A. Abutalib, MD, and Ola Landgren, MD, PhD  /  April 25, 2018

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Landgren review the underlying data that shaped the updated International Myeloma Working Group (IMWG) diagnostic criteria for multipl...

Hematologic Malignancies

Microangiopathic Hemolytic Anemia and Thrombocytopenia: Questions

Syed A. Abutalib, MD, and Jean M. Connors, MD  /  August 25, 2015

Hematology Expert Review is an occasional feature that includes a case report followed by questions, answers, and expert commentary. In the July 25 issue of The ASCO Post, part 1 of a case report was published and focused on diagnosis (see summary below). Here, in part 2, the management of this case...

Lymphoma

Questions: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

Syed Abutalib, MD, and Rimas V. Lukas, MD  /  October 25, 2015

Hematology Expert Review is an occasional feature that includes a case report followed by questions,answers, and expert commentary. In this issue of The ASCO Post, Drs. Abutalib and Lukas present part 1 of a case report on primary diffuse large B-cell lymphoma. Part 2 will be published in an upcomin...

Lymphoma

Answers: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

Syed Abutalib, MD, and Rimas V. Lukas, MD  /  October 25, 2015

Question 1: What is the most likely diagnosis for this patient? Correct Answer: B. Primary central nervous system lymphoma. Expert Perspective In an immunocompetent host, the differential diagnosis of isolated or multiple brain lesion(s) includes autoimmune etiologies such as neurosarcoidosis, mu...

Lymphoma

Questions: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

Syed A. Abutalib, MD, and Rimas V. Lukas, MD  /  November 10, 2015

The ASCO Post is pleased to present Hematology Expert Review, an occasional feature that includes a case report detailing a particular hematologic condition followed by questions. Answers to each question appear here with expert ­commentary. In the October 25 issue of The ASCO Post, part 1 of a cas...

Lymphoma

Answers: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

Syed A. Abutalib, MD, and Rimas V. Lukas, MD  /  November 10, 2015

Question 1: What is next best step in the management of this patient? Correct Answer: C. Ophthalmoscopy/slit lamp examination. Expert Perspective Ophthalmic involvement should be sought by noninvasive procedures such as slit lamp examination and ophthalmoscopy and abnormal findings must be confir...

Lymphoma

Q: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

Syed Abutalib, MD, and Rimas V. Lukas, MD  /  December 25, 2015

The ASCO Post is pleased to present Hematology Expert Review, an occasional feature that includes a case report detailing a particular hematologic condition followed by questions. Answers to each question appear on page 84 with expert commentary. In the November 10 issue of The ASCO Post, part 2 of...

Advertisement

Advertisement



Advertisement